Your session is about to expire
← Back to Search
Endovascular Device
Nellix System for Abdominal Aortic Aneurysm (EVAS IDE Trial)
N/A
Waitlist Available
Led By Jeffrey Carpenter, MD
Research Sponsored by Endologix
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-procedure to 5 years
Awards & highlights
EVAS IDE Trial Summary
This trial is testing a new device to treat abdominal aortic aneurysms. The goal is to see if it is safe and effective.
Eligible Conditions
- Abdominal Aortic Aneurysm
EVAS IDE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ post-procedure to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-procedure to 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Major Adverse Events at 30 Days
Treatment Success at 1 Year
Secondary outcome measures
Adverse Events
Aneurysm Rupture
Clinical Utility Outcomes
+8 moreEVAS IDE Trial Design
1Treatment groups
Experimental Treatment
Group I: Nellix SystemExperimental Treatment1 Intervention
Nellix Endovascular Aneurysm Sealing System is the only arm for this study. This is a single arm study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nellix System
2013
N/A
~340
Find a Location
Who is running the clinical trial?
EndologixLead Sponsor
22 Previous Clinical Trials
3,639 Total Patients Enrolled
Jeffrey Carpenter, MDPrincipal InvestigatorCooper Hospital, Camden, NJ
1 Previous Clinical Trials
98 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger